Argen X (Belgium) Performance
| ARGX Stock | EUR 590.80 8.40 1.44% |
On a scale of 0 to 100, Argen X holds a performance score of 16. The firm shows a Beta (market volatility) of 0.0635, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Argen X's returns are expected to increase less than the market. However, during the bear market, the loss of holding Argen X is expected to be smaller as well. Please check Argen X's coefficient of variation, jensen alpha, and the relationship between the downside deviation and standard deviation , to make a quick decision on whether Argen X's price patterns will revert.
Risk-Adjusted Performance
16 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Argen X are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. Even with relatively uncertain basic indicators, Argen X reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 1.2 B | |
| Total Cashflows From Investing Activities | -347.1 M |
Argen |
Argen X Relative Risk vs. Return Landscape
If you would invest 46,810 in Argen X on August 30, 2024 and sell it today you would earn a total of 12,270 from holding Argen X or generate 26.21% return on investment over 90 days. Argen X is generating 0.3739% of daily returns and assumes 1.7541% volatility on return distribution over the 90 days horizon. Simply put, 15% of stocks are less volatile than Argen, and 93% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Argen X Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Argen X's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Argen X, and traders can use it to determine the average amount a Argen X's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2131
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ARGX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.75 actual daily | 15 85% of assets are more volatile |
Expected Return
| 0.37 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.21 actual daily | 16 84% of assets perform better |
Based on monthly moving average Argen X is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Argen X by adding it to a well-diversified portfolio.
Argen X Fundamentals Growth
Argen Stock prices reflect investors' perceptions of the future prospects and financial health of Argen X, and Argen X fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Argen Stock performance.
| Return On Equity | -0.31 | |||
| Return On Asset | -0.16 | |||
| Operating Margin | (2.97) % | |||
| Current Valuation | 17.99 B | |||
| Shares Outstanding | 55.47 M | |||
| Price To Earning | (19.01) X | |||
| Price To Book | 7.26 X | |||
| Price To Sales | 72.52 X | |||
| Revenue | 497.28 M | |||
| EBITDA | (391.48 M) | |||
| Cash And Equivalents | 2.6 B | |||
| Cash Per Share | 47.17 X | |||
| Total Debt | 9.7 M | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 53.95 X | |||
| Cash Flow From Operations | (606.81 M) | |||
| Earnings Per Share | (11.03) X | |||
| Total Asset | 2.85 B | |||
About Argen X Performance
Assessing Argen X's fundamental ratios provides investors with valuable insights into Argen X's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Argen X is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Ltd, Universit Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands. ARGENX SE operates under Pharmaceuticals And Biosciences classification in Belgium and is traded on Brussels Stock Exchange. It employs 650 people.Things to note about Argen X performance evaluation
Checking the ongoing alerts about Argen X for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Argen X help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the revenue of 497.28 M. Net Loss for the year was (408.26 M) with loss before overhead, payroll, taxes, and interest of (52.25 M). | |
| Argen X has accumulated about 2.6 B in cash with (606.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 47.17. |
- Analyzing Argen X's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Argen X's stock is overvalued or undervalued compared to its peers.
- Examining Argen X's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Argen X's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Argen X's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Argen X's stock. These opinions can provide insight into Argen X's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Argen Stock Analysis
When running Argen X's price analysis, check to measure Argen X's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Argen X is operating at the current time. Most of Argen X's value examination focuses on studying past and present price action to predict the probability of Argen X's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Argen X's price. Additionally, you may evaluate how the addition of Argen X to your portfolios can decrease your overall portfolio volatility.